Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with ulcerative colitis (UC), confirmed by a previous colonoscopy along with matching test results and symptoms over time.
- Your ulcerative colitis affects at least the lower part of your large intestine (the rectum and sigmoid colon), confirmed by a colonoscopy at the start of the study.
- Your disease is considered mild to moderate in severity, based on a specific scoring system called the Partial Mayo Score (PMS), with a score between 3 and 8 (confirm with trial site).
- You have been taking your current medication for at least 4 weeks before joining the study.
Who may not be able to join:
- You have been diagnosed with Crohn's disease or pouchitis (inflammation of a surgically created internal pouch).
- Your disease is considered severe, meaning your Partial Mayo Score is higher than 8.
- You have taken antibiotics within the last 2 weeks before starting the study.
- Your medication dose has been changed in the last 4 weeks before the study, or you would need to change it during the 12-week study period.
- You have used probiotic products (whether prescribed by a doctor or bought over the counter) within the 2 weeks before joining the study.
- You have used anti-inflammatory painkillers (known as NSAIDs, such as ibuprofen) within 1 week before the study or plan to use them during the 12-week study period.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +60391458610
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Gut microbiome analysis; Faecal Calprotectin Level; C-reactive Protein (CRP) Level; Erythrocyte Sedimentation Rate (ESR) Level; Change in White Blood Cell (WBC) Count; Change in Serum Metabolite Profile; Change in Proinflammatory Cytokine Gene Expression
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.